Glaxosmithkline | GSK - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.84B 205M 2026-09
Amgen USD 1.68B 40M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Aurora Cannabis CAD 40.89M 515K 2026-06
Bausch Health Companies USD 834M 67M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Canopy Growth CAD 33.99M 2.83M 2026-06
Corcept Therapeutics USD 142.04M 14.86M 2026-09
Drreddys Laboratories INR 28.08B 13.61B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
GlaxoSmithKline GBP 2.16B 39M 2026-09
Glaxosmithkline GBP 2.38B 264M 2026-09
J&J USD 6.25B 168M 2026-09
Merck USD 2.86B 25M 2026-09
Novartis USD 3.08B 163M 2026-09
Pacira USD 950.8M 858.99M 2026-09
Perrigo USD 271.7M 3.01B 2026-09
Pfizer USD 3.28B 132M 2026-09
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 2.08B 2.04B 2026-09
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.31B 325M 2026-09
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
Takeda JPY 271.71B 14.8B 2026-09
Teva Pharmaceutical Industries USD 1.01B 27M 2026-09
Zoetis USD 582M 10M 2026-09